HCPCS Codes Similar to G0010

HCPCS Codes Similar to “G0010” Code.
Administration of hepatitis b vaccine

G0008 Administration of influenza virus vaccine Code added date: 19940101 Code effective date: 19960101 TXT \| PDF \| XML \| JSON	G0009 Administration of pneumococcal vaccine Code added date: 19940101 Code effective date: 19960101 TXT \| PDF \| XML \| JSON
G9141 Influenza a (h1n1) immunization administration (includes the physician counseling the patient/family) Code added date: 20090901 Code effective date: 20130101 TXT \| PDF \| XML \| JSON	G9142 Influenza a (h1n1) vaccine, any route of administration Code added date: 20090901 Code effective date: 20130101 TXT \| PDF \| XML \| JSON
M0201 Administration of pneumococcal, influenza, hepatitis b, and/or covid-19 vaccine inside a patient's home; reported only once per individual home per date of service when such vaccine administration(s) are performed at the patient's home Code added date: 20210608 Code effective date: 20240101 TXT \| PDF \| XML \| JSON	M0220 Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring Code added date: 20211208 Code effective date: 20241213 TXT \| PDF \| XML \| JSON
M0221 Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency Code added date: 20211208 Code effective date: 20241213 TXT \| PDF \| XML \| JSON	M0222 Intravenous injection, bebtelovimab, includes injection and post administration monitoring Code added date: 20220211 Code effective date: 20241213 TXT \| PDF \| XML \| JSON
M0223 Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency Code added date: 20220211 Code effective date: 20241213 TXT \| PDF \| XML \| JSON	M0224 Intravenous infusion, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, includes infusion and post administration monitoring Code added date: 20240322 Code effective date: 20240322 TXT \| PDF \| XML \| JSON
M0235 Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, not otherwise classified, first dose Code added date: 20251001 Code effective date: 20251001 TXT \| PDF \| XML \| JSON	M0236 Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, not otherwise classified, second dose Code added date: 20251001 Code effective date: 20251001 TXT \| PDF \| XML \| JSON
M0237 Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose Code added date: 20250124 Code effective date: 20250124 TXT \| PDF \| XML \| JSON	M0238 Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, second dose Code added date: 20250124 Code effective date: 20250124 TXT \| PDF \| XML \| JSON